Orchestra BioMed (OBIO) announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation, AVIM, Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025. The presentation will showcase AVIM Therapy as a novel, device-based therapeutic approach targeting hypertensive heart disease progression and its potential to redefine standards of care. The keynote presentation will provide a comprehensive overview of clinical and mechanistic AVIM Therapy results from pilot and long-term follow-up studies, highlighting the therapy’s consistent favorable clinical impact on blood pressure and cardiac function: Immediate, substantial, and sustained blood pressure reduction; Favorable impact on cardiac hemodynamics after 24 months of treatment; Improvement in echocardiographic measures of diastolic function; Potential to halt hypertensive heart disease progression
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed announces new data from AVIM therapy program
- Orchestra BioMed price target lowered to $10 from $12 at H.C. Wainwright
- Orchestra BioMed announces publication of data on effects of AVIM
- Orchestra BioMed downgraded to Neutral from Buy at BTIG
- Orchestra BioMed Reports Q2 2025 Financial Results